

International Patent Class (Main): A61K-037/54; A61K-047/28
 International Patent Class (Additional): A23L-001/03

009934327

WPI Acc No: 1994-202039/199425

Orally administered therapeutic protein compsn. - comprises combination
 of protein and stabilising agent in aq. soln. to form microcapsules.

Patent Assignee: UNIV CINCINNATI (UYCI-N)

Inventor: LITWIN A; MICHAEL J G; MICHAEL J; GABRIEL M J; GABRIEL M

Number of Countries: 023 Number of Patents: 013

Patent Family:

| Patent No | Kind | Date | Applicat No | Kind | Date | Week |
|-------------|------|----------|-------------|------|----------|----------|
| EP 603992 | A1 | 19940629 | EP 93300005 | A | 19930104 | 199425 B |
| AU 9331045 | A | 19940707 | AU 9331045 | A | 19930105 | 199431 |
| CA 2086631 | A | 19940623 | CA 2086631 | A | 19930104 | 199433 |
| NZ 245618 | A | 19941026 | NZ 245618 | A | 19930106 | 199442 |
| JP 7010771 | A | 19950113 | JP 9331074 | A | 19930106 | 199512 |
| AU 664222 | B | 19951109 | AU 9331045 | A | 19930105 | 199601 |
| EP 603992 | B1 | 19961009 | EP 93300005 | A | 19930104 | 199645 |
| DE 69305313 | E | 19961114 | DE 605313 | A | 19930104 | 199651 |
| | | | EP 93300005 | A | 19930104 | |
| US 5591433 | A | 19970107 | US 91719160 | A | 19910621 | 199708 |
| | | | US 92994932 | A | 19921222 | |
| | | | US 95405604 | A | 19950120 | |
| ES 2095001 | T3 | 19970201 | EP 93300005 | A | 19930104 | 199712 |
| CA 2086631 | C | 19981006 | CA 2086631 | A | 19930104 | 199850 |
| SG 52402 | A1 | 19980928 | SG 964016 | A | 19930104 | 199903 |
| EP 603992 | B2 | 20001206 | EP 93300005 | A | 19930104 | 200064 |

Priority Applications (No Type Date): US 92994932 A 19921222; US 91719160 A
 19910621; US 95405604 A 19950120

Cited Patents: BE 621398; EP 130163; GB 2178313; JP 56142211; 2.Jnl.Ref

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

EP 603992 A1 E 17 A61K-009/50

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
 NL PT SE

AU 9331045 A A61K-009/64

CA 2086631 A A61K-009/50

NZ 245618 A A61K-037/02

JP 7010771 A 11 A61K-038/00

AU 664222 B A61K-009/64 Previous Publ. patent AU 9331045

EP 603992 B1 E 15 A61K-009/50

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
 NL PT SE

DE 69305313 E A61K-009/50 Based on patent EP 603992

US 5591433 A 10 A61K-039/00 CIP of application US 91719160

Cont of application US 92994932

ES 2095001 T3 A61K-009/50 Based on patent EP 603992

CA 2086631 C A61K-009/50

SG 52402 A1 A61K-009/50

EP 603992 B2 E A61K-009/50

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
 NL PT SE

Abstract (Basic): EP 603992 A

An orally administered therapeutic protein (A) compsn. comprises a protein microencapsulated, in the absence of organic solvents, with a water based enteric coating.

Also claimed are: (1) a method for administering (A); and (2) a method for forming the therapeutic compsn. by forming an aq. solution contg. (A) and microencapsulating the protein with an aq. solution of an enteric coating with no organic solvents.

The enteric coating is a water based emulsion ethylacrylate methacrylic acid copolymer. (A) is selected from allergenic proteins digested fragments of allergenic proteins, viral vaccines, bacterial vaccines, protozoal vaccines, toxoids, glycoproteins, insulin, hGF, myelin basic protein, collagen S antigen, or TGF-beta. The compsn. further comprises a stabilising sugar e.g. lactose and water suspended aluminium salt.

USE/ADVANTAGE - (A) is administered orally and the coating protects it as it passes through the stomach. Upon reacting the small intestines, the basic pH of the intestinal juices dissolves the coating allowing the protein to be released. The stabilisation agent protects the protein from denaturation during encapsulation. (A), when released, induces an antigen specific response which has the specificity of the native molecule, hence it can be used as an allergen for treating human allergies.

Dwg.0/11

Abstract (Equivalent): EP 603992 B

An orally administrable therapeutic composition comprising a therapeutic protein microencapsulated in the complete absence of organic solvents with a water based enteric coating.

(Dwg.0/11)

Abstract (Equivalent): US 5591433 A

An orally administrable therapeutic composition comprises an immunogen microencapsulated in the complete absence of organic solvents with a water based enteric coating where the immunogen has an immunotherapeutic effect against an allergen in a warm blood animal.

Dwg.0/11

Derwent Class: B04

International Patent Class (Main): A61K-009/50; A61K-009/64; A61K-037/02; A61K-038/00; A61K-039/00

International Patent Class (Additional): A61K-009/16; A61K-009/52; A61K-013/00; A61K-037/26; A61K-037/36; A61K-037/43; A61K-038/18; A61K-038/22; A61K-038/28; A61K-039/002; A61K-039/02; A61K-039/12; A61K-039/35; A61K-045/00; A61K-047/26; A61K-047/32; B01J-013/02; B01J-013/06